APOA1 Genotype

Most people learn their HDL number and stop there. But the gene behind HDL, called APOA1, carries inherited variations that shape how well your body builds and uses this cholesterol-clearing system, and standard lipid panels cannot see any of it.

Your APOA1 (apolipoprotein A-I) genotype is set at conception and never changes. It can help explain why some people with normal HDL still develop heart disease, why others have unusually low HDL their whole lives, and why a small group carry rare variants that cause inherited diseases affecting the kidneys, heart, or nervous system.

What This Gene Actually Does

APOA1 is the instruction manual for apolipoprotein A-I, the main protein scaffold of HDL particles. Without this protein, HDL cannot form properly, and the body loses much of its ability to pull cholesterol out of artery walls and ship it back to the liver.

Resequencing of the APOA1 gene in more than 10,000 people found 40 different variants. Only 7 of them were common (carried by more than 1 in 100 people). The rest were rare changes that alter the protein in subtle ways. A few common variants sit in the regulatory region of the gene, where they can turn the gene up or down, while most of the rare ones change the protein itself.

What Different Variants Can Mean

Not all APOA1 variants behave the same way. Some shift HDL cholesterol modestly without changing disease risk. Others cause profound HDL deficiency. A specific group causes a rare inherited condition where misshapen apoA-I protein builds up in organs.

• Common regulatory variants: small DNA changes such as -75 G/A and +83 C/T sit in the switch region of the gene and nudge apoA-I production up or down. These are among the most studied APOA1 variants in research literature, though coverage on commercial genotyping panels varies.
• Rare protein-changing variants: found in roughly 1 in 370 people, these can sharply reduce apoA-I and HDL cholesterol and have been linked to about 1.7 times the risk of heart attack in a large Danish cohort.
• Loss-of-function mutations: carrying two damaged copies causes apoA-I deficiency, with HDL cholesterol that is barely detectable on a standard panel.
• Amyloidogenic mutations: a separate group of variants produces protein that misfolds and deposits in tissues, causing a rare inherited disease called apoA-I amyloidosis. In the same Danish resequencing study, about 0.41 percent of people carried a variant in the regions of the gene associated with amyloidosis, making these variants slightly more common than other rare protein-changing variants.

Heart Disease Risk

This is where APOA1 genotype gets interesting, and counterintuitive. For decades, doctors assumed that higher HDL meant a lower heart attack risk. APOA1 genetics has helped show that the story is more complicated.

Common APOA1 variants that raise apoA-I and HDL cholesterol have not been shown to lower the risk of ischemic heart disease or heart attack in large genetic studies. A Mendelian randomization analysis (a method that uses inherited variants to test whether higher levels of a substance cause lower disease risk) found no protective effect of genetically higher apoA-I on coronary artery disease. Multivariable analyses further show that the apparent link between higher apoA-I or HDL cholesterol and lower heart disease risk shrinks to nothing once apoB-carrying particles are accounted for. This does not mean HDL is irrelevant. It means that simply pushing the HDL number up does not automatically protect arteries, and a gene variant that raises HDL is not a free pass.

Rare APOA1 variants tell a different story. In the population-based resequencing study, people carrying rare protein-changing variants (about 0.27 percent of those tested) had substantially reduced apoA-I and HDL cholesterol and roughly 1.7 times the risk of myocardial infarction (hazard ratio 1.72). Notably, this excess heart attack risk was largely driven by a single variant called A164S, which was not itself associated with lower apoA-I or HDL cholesterol levels. The takeaway: a rare, damaging APOA1 variant matters, but the mechanism may go beyond simply lowering HDL.

Reconciling the Surprising Heart Findings

It can feel contradictory that rare APOA1 variants raise heart attack risk while common ones that raise HDL do nothing. The resolution is that APOA1 genotype is not a single dial labeled good or bad. Common regulatory variants mostly change how much apoA-I you make, and the human body has many ways to compensate for a small shift. Rare variants change what the protein actually looks like and how well it functions. The A164S finding suggests that some rare variants may raise heart attack risk through pathways that are not captured by your HDL number at all, such as effects on how HDL particles interact with blood vessels or clotting. The lesson is that a normal HDL on a lipid panel does not necessarily mean a rare APOA1 variant is harmless.

Other Disease Connections

APOA1 variants have been linked to several conditions outside the heart, mostly in observational studies of specific populations. None of these associations are strong enough to make APOA1 genotype a standalone diagnostic test for any of them, but they help explain why the gene shows up in research on multiple body systems.

• Early-onset Alzheimer's disease: an initial study reported that carriers of the -75 A allele had higher risk of early-onset Alzheimer's, with two-copy carriers developing symptoms about 8 years earlier on average. A later replication attempt in three independent European samples did not confirm the Alzheimer's risk association, though it did find a link to cognitive decline. The evidence here is mixed.
• Lung injury after major surgery: people with the -75 AA genotype had higher rates of acute lung injury after cardiopulmonary bypass surgery and worse 30-day survival in a study of 900 patients.
• Renal cell cancer: the -75 AA genotype was linked to about 2.1 times the odds of renal cancer compared with the more common GG genotype in a Chinese case-control study of 432 people.
• Schizophrenia: a separate APOA1 variant (rs5072) showed a statistically significant association with schizophrenia susceptibility in a study of nearly 5,000 participants.

Rare Inherited Diseases

A small set of APOA1 mutations cause distinct hereditary conditions. These are uncommon, but they matter because they often show up in families with a clear pattern of organ disease that no one has been able to explain.

Hereditary apoA-I amyloidosis is caused by specific coding mutations that make the protein misfold and deposit in organs. Where it deposits depends on where in the gene the mutation sits. Mutations in codons 1 to 75 tend to involve the liver and kidneys; mutations in codons 173 to 178 tend to involve the heart and voice box. Newer reports describe forms that affect the kidney filters and the retina. These conditions are easy to miss because patients often present with isolated organ failure long before anyone thinks of an inherited cause.

Severe apoA-I deficiency, caused by loss-of-function mutations in both copies of the gene, produces extremely low HDL cholesterol that stands out on a routine lipid panel. A combined promoter and nonsense mutation in a 12-year-old boy was enough to cause this picture.

Why This Is a Once-in-a-Lifetime Test

Your APOA1 genotype is set at conception. The result you get today is the same one you would get in 20 years. There is no retesting required to track a trend. The value of this test comes from what you do with the result over the rest of your life, not from measuring it more than once.

What you should track instead are the downstream measurements: HDL cholesterol, apolipoprotein A-I protein levels, and broader markers of heart and metabolic health. If you carry a variant linked to lower HDL or higher heart disease risk, an annual lipid panel becomes more important, not less. If you carry a variant linked to apoA-I amyloidosis, periodic checks of kidney function, urinary protein, and cardiac markers may be appropriate depending on which mutation you carry.

When Results Can Be Misleading

Genetic tests for APOA1 have their own set of pitfalls. These are different from the confounders that affect a blood biomarker like HDL cholesterol.

• Variant panel coverage: the assay only detects the specific variants it is designed to find. A normal result does not rule out a rare variant in the same gene that the panel was not built to catch.
• Ancestry-specific frequencies: some APOA1 variants are common in one population and rare in another. The clinical meaning of carrying a variant depends partly on which population the research was done in.
• Variants of uncertain significance: sequencing can find DNA changes that have not been studied enough to know whether they cause disease. These results can be confusing and sometimes need follow-up by a genetic counselor.
• Clinical-grade versus consumer panels: if you previously saw an APOA1 variant on a direct-to-consumer report, the result may differ from a clinical-grade test in coverage, accuracy, and the variants reported.

What to Do With an Unexpected Result

Most APOA1 genotype findings do not require immediate action. They reshape how often you should check related markers and how aggressively you should manage risk factors you already have some control over.

If you carry a common variant linked to lower HDL or higher cardiovascular risk, the right move is a fuller cardiovascular workup. That means a lipid panel with apoB and Lp(a), a coronary calcium scan if you are over 40 or have other risk factors, and tighter targets for blood pressure, blood sugar, and body composition. The variant raises your baseline risk; the workup tells you where you actually stand right now.

If a rare, potentially disease-causing variant is reported, especially one in the amyloidosis-causing region of the gene, the next step is referral to a genetic counselor. They can confirm the result by a second method, assess penetrance for your specific variant, and help you decide whether and how to share the result with biological relatives, who carry a 50 percent chance of having inherited the same variant.